Coherus BioSciences shares are trading lower. Truist Securities maintained a Buy rating on the stock and lowered its price target from $24 to $22.
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences shares are trading lower after Truist Securities maintained a Buy rating on the stock but lowered its price target from $24 to $22.
June 20, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Coherus BioSciences shares are trading lower after Truist Securities lowered its price target from $24 to $22, while maintaining a Buy rating.
The lowered price target by Truist Securities is likely to have a negative short-term impact on Coherus BioSciences' stock price. However, the maintained Buy rating suggests that the stock is still considered a good investment in the long term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100